EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 26-Oct-2026 22:16 ET (27-Oct-2026 02:16 GMT/UTC)

Mayo Clinic researchers uncover critical link in the immune response to cancer

Mayo Clinic
Peer-Reviewed Publication

Researchers at Mayo Clinic have uncovered a previously hidden step in how the immune system prepares to fight cancer, a discovery that could help scientists develop more effective and longer-lasting cancer immunotherapies.

Journal: Nature Communications

Metabolic reprogramming and epigenetic regulation: The dual role of lactate and lactylation in pancreatic ductal adenocarcinoma progression and therapeutics

FAR Publishing Limited
Peer-Reviewed Publication

Recent findings published in Current Molecular Pharmacology reveal that lactate, once dismissed as a metabolic waste product, drives pancreatic cancer progression through dual roles as a fuel and signaling molecule. The study highlights lactylation—a novel protein modification—as a key epigenetic regulator in tumor growth, immune suppression, and therapy resistance.

Journal: Current Molecular Pharmacology

PVT1&EIF4A1 promote metastasis through regulating Notch-1 signaling pathway via STC-1 in gastric cancer

FAR Publishing Limited
Peer-Reviewed Publication

A new study in Current Molecular Pharmacology reveals that the lncRNA PVT1 binds to the translation factor EIF4A1 and drives gastric cancer progression by upregulating STC1. STC1 then activates Notch1 signalling and epithelial–mesenchymal transition, promoting metastasis. The findings identify STC1 as a potential therapeutic target and diagnostic marker for aggressive gastric cancer.

Journal: Current Molecular Pharmacology

MiR-29a as a molecular target in cancer: Prevention strategies with natural products

FAR Publishing Limited
Peer-Reviewed Publication

A study published in Current Molecular Pharmacology highlights the dual role of miR-29a in cancer and explores how natural bioactive compounds—such as curcumin, EGCG, and resveratrol—can modulate its expression through epigenetic and signaling pathways, offering new avenues for cancer prevention.

Journal: Current Molecular Pharmacology

Gramine suppresses triple-negative breast cancer by inducing ferroptosis via CUL3-mediated ubiquitination of MTDH

FAR Publishing Limited
Peer-Reviewed Publication

A study published in Current Molecular Pharmacology reveals that the natural alkaloid gramine selectively inhibits triple‑negative breast cancer by triggering ferroptosis through a novel CUL3‑MTDH axis. Gramine binds CUL3, reducing MTDH ubiquitination and degradation, which downregulates ferroptosis suppressors SLC3A2 and GPX4. In vivo, gramine significantly suppressed tumor growth with minimal toxicity, positioning it as a promising therapeutic candidate for this aggressive cancer.

Journal: Current Molecular Pharmacology

The mechanism of lactylation modification in the progression and drug resistance of lung cancer

FAR Publishing Limited
Peer-Reviewed Publication

A review published in Current Molecular Pharmacology reveals that lactylation—a novel protein modification driven by lactate—plays a critical role in lung cancer progression and therapy resistance. The study outlines a “reflex arc” of writers, erasers, and readers, highlighting how histone and non‑histone lactylation drive immune escape, metabolic rewiring, and resistance to chemotherapy, immunotherapy, and EGFR‑TKIs. The authors propose targeting the lactate‑lactylation axis as a promising therapeutic strategy.

Journal: Current Molecular Pharmacology

Low-cost lensfree holography and AI enable reliable automated HER2 scoring for breast cancer pathology

BMEF (BME Frontiers)
Peer-Reviewed Publication

Human epidermal growth factor receptor 2 (HER2) is a critical protein in cancer cell growth that signifies the aggressiveness of breast cancer (BC) and helps predict its prognosis. Researchers at UCLA have introduced a compact and cost-effective lensfree holography device integrated with deep learning for rapid, automated HER2 scoring of immunohistochemically stained breast tissue sections.

Journal: BME Frontiers
Funder: This project is supported by the NSF Biophotonics Program.

Eliminating cancer cells that survive KRAS inhibition: A potential way to prevent relapse

Chiba University
Peer-Reviewed Publication

Cancers caused by mutations in the KRAS gene are challenging to treat, and current KRAS inhibitor therapies can leave behind reversible drug-tolerant persister (DTP) cells that survive therapy, contributing to tumor regrowth and relapse. Researchers from Chiba University found that these surviving cells adapt by reshaping their metabolism. By targeting these metabolic adaptations, the team succeeded in reducing the survival of DTP cells. The findings may help develop therapies to reduce relapse in KRAS-mutant cancers.

Journal: Communications Biology
Funder: Japan Society for the Promotion of Science, SGH Foundation, Suzuken Memorial Foundation

New drug candidate shows promise in overcoming chemotherapy resistance in small cell lung cancer

Hefei Institutes of Physical Science, Chinese Academy of Sciences
Peer-Reviewed Publication

Recently, a research team led by Prof. LIU Qingsong at the Institute of Health and Medical Technology, the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, has discovered a new drug candidate that may help overcome chemotherapy resistance in small cell lung cancer (SCLC).

Journal: Signal Transduction and Targeted Therapy

Researchers develop a new prodrug and localised drug delivery platform for selective treatment of cancer

University of Eastern Finland
Peer-Reviewed Publication

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumour microenvironments to improve therapeutic efficacy, with promising results.

Journal: Bioorganic Chemistry